VVUS - VIVUS, Inc. (NASDAQ Stock)

[rtace]

Strong News out today

VIVUS Receives FDA Approval of Evamist NDA
Monday July 30, 8:00 am ET
VIVUS Eligible to Receive Milestone Payment of $140,000,000 from KV Pharmaceutical

Chart Looks Good
Closes above 5.90 could be a breakout play

http://stockcharts.com/h-sc/ui?s=VVU...d=p47776803474

[Leo38Cheng]

Hey guys, there's news out on VVUS yesterday and today was wondeing what you guys think of it. thanks!

*VIVUS Announces Date of First Quarter 2009 Financial Results and Conference CallGlobeNewswire(Fri 7:00am)
*Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity

[Leo38Cheng]

brought in at $4.38, looking for good news on earnings and also test result.

[fz4fun]

Big news for this one--may run today:

Vivus Drug For Erectile Dysfunction Meets Goals; Shares Up
7:46 AM ET 11/18/09 | Dow Jones
RELATED QUOTES


4:00 PM ET 11/17/09
Symbol Last % Chg
VVUS
8.57 0.00%
Real time quote.

DOW JONES NEWSWIRES

Vivus Inc.'s (VVUS) drug candidate to treat erectile dysfunction was found safe and effective in a late stage trial, putting the company on course to file a new-drug application with the Food and Drug Administration by early 2011.

Shares were up 9.7% at $9.40 in recent premarket trading. The stock was up 61% this year through Tuesday's close.

Chief Executive Leland Wilson said the findings show Vivus' treatment may work faster and have less side effects than current treatments. "Erectile dysfunction is a significant problem among more than half of all men over the age of 40," he added. "While sales of currently available ED therapies exceed $3.8 billion a year, persistent switching by patients suggests that patients are less than satisfied with current therapies."

The study included 646 patients, who underwent a four-week nontreatment period, followed by 12 weeks using either using a either 50 milligrams, 100 milligrams or 200 milligrams or a placebo. The study found nearly 80% of ****** attempts were successful at a 200-milligram dose, and full efficacy was reported in 30 minutes or less. Efficacy was maintained for all doses from 30 minutes to beyond six hours.

The ED treatment news comes as Vivus plans to shortly file a new drug application for its obesity drug candidate following recent positive results from late-stage studies.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

[greencat]

VVUS broke a small trendline. Still making the cup pattern. 3rd higher low. I expect a nice move up is coming very soon.

VVUS Chart

[greencat]

VVUS showing a cup pattern. There is an excellant chance VVUS will complete the cup pattern. Some resistance at $9.00 but I expect it to break through it and make a move to $11.50 or better..

VVUS Chart